← Drug database

Osvyrti (denosumab)

BiosimilarAdditional monitoring
Region
🇪🇺 EU
Active substance
denosumab
Company
Accord Healthcare S.L.U.
Status
Authorised
Therapeutic area
Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal
CHMP opinion
Thu 27 Mar 2025
EU approval
Mon 26 May 2025
Designations
Biosimilar, Additional monitoring
Application
EMEA/H/C/006399
ATC
M05BX04
Official record
www.ema.europa.eu

Indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures.Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

Regulatory milestones

Wed 29 Oct 2025🇺🇸 FDA approval

FDA approves biosimilar Osvyrti (denosumab-desu)

Accord Biopharma Inc.; BLA761424; Biosimilar; injectable · source

Same substance in other markets

Follow Osvyrti

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.